Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.71 |
| ▸ | NAPEPLD | Q6IQ20 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | DNM1L | O00429 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180456 | 1.00 | PDE10A (0.71) | PDE10ANAPEPLDHSD11B1BRD4KDM4E | |
| SCHEMBL2180281 | 0.84 | PDE10A (0.54) | PDE10ANAPEPLDHSD11B1BRD4DNM1L | |
| SCHEMBL2180271 | 0.84 | PDE10A (0.54) | PDE10ANAPEPLDHSD11B1BRD4DNM1L | |
| SCHEMBL2182187 | 0.84 | PDE10A (0.62) | PDE10AHSD11B1KDM4E | |
| SCHEMBL2182192 | 0.84 | PDE10A (0.62) | PDE10AHSD11B1KDM4E | |
| SCHEMBL2178158 | 0.83 | PDE10A (0.55) | PDE10AKDM4E | |
| SCHEMBL2178168 | 0.83 | PDE10A (0.55) | PDE10AKDM4E | |
| SCHEMBL2178291 | 0.81 | PDE10A (0.73) | PDE10AKDM4E | |
| SCHEMBL2178286 | 0.81 | PDE10A (0.73) | PDE10AKDM4E | |
| SCHEMBL2181159 | 0.76 | PDE10A (0.47) | PDE10ANAPEPLDHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | claimed |
| EP-2342191-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-07-13 | — | — | EP | claimed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | claimed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | claimed |
| EP-2342191-B1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2342191-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-07-07 | — | — | US | disclosed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166135-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | PDE10A, PDE3A, PDE3B | PDE10A 1/4885NAPEPLD 1508/4885HSD11B1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.